Cargando…

Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera

OBJECTIVE: To evaluate the pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after a single subcutaneous injection in the abdomen of 150 or 300 mg Depo-Provera and compare results to two injections of Depo-SubQ Provera 104 given 3 months apart. DESIGN: Partially randomized, multic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halpern, Vera, Brache, Vivian, Taylor, Douglas, Lendvay, Anja, Cochón, Leila, Jensen, Jeffrey T., Dorflinger, Laneta J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier for the American Society for Reproductive Medicine 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051852/ https://www.ncbi.nlm.nih.gov/pubmed/33485608 http://dx.doi.org/10.1016/j.fertnstert.2020.11.002

Ejemplares similares

Suppression of ovulation and pharmacokinetics following subcutaneous administration of various doses of Depo-Provera®: a randomized trial
por: Halpern, Vera, et al.
Publicado: (2021)

A randomized crossover study to evaluate local tolerability following subcutaneous administration of a new depot medroxyprogesterone acetate contraceptive formulation()
por: Halpern, Vera, et al.
Publicado: (2023)

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
por: Taylor, Douglas J., et al.
Publicado: (2022)

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
por: Lam, Clarissa, et al.
Publicado: (2016)

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer*
por: Bloom, H. J. G.
Publicado: (1971)

Incidental Finding of Persistent Hydatidiform Mole in an Adolescent on Depo-Provera
por: Akinlaja, Olukayode, et al.
Publicado: (2016)

Diabetes insipidus in a patient with PCOS treated with Depo-Provera
por: Martinez, Amanda I, et al.
Publicado: (2022)

Return to ovulation after Sayana Press is injected every 4 months for one year: Empirical and pharmacokinetic/pharmacodynamic modeling results()
por: Taylor, Douglas J., et al.
Publicado: (2022)

Precipitous Delivery Masquerading as Biliary Colic in the Setting of Depo-Provera® Failure
por: Chang, Allen D, et al.
Publicado: (2020)

Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial()()
por: Nanda, Kavita, et al.
Publicado: (2016)

Comparison of Sexual Dysfunction in Women Using Depo-Medroxyprogesterone Acetate (DMPA) and Cyclofem
por: Ozgoli, Giti, et al.
Publicado: (2015)

Uterine leiomyoma and its association with menstrual pattern and history of depo-medroxyprogesterone acetate injections
por: Amanti, L, et al.
Publicado: (2011)

Effects of Long-term Use of Depo-medroxyprogesterone Acetate on Lipid Metabolism in Nepalese Women
por: Yadav, Binod Kumar, et al.
Publicado: (2011)

Changes in body weight and blood pressure among women using Depo-Provera injection in Northwest Ethiopia
por: Zerihun, Muluken Fekadie, et al.
Publicado: (2019)

Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out
por: Hapgood, Janet P.
Publicado: (2020)

Contraceptive effectiveness, pharmacokinetics, and safety of Sayana® Press when injected every four months: a multicenter phase 3 trial
por: Deese, Jennifer, et al.
Publicado: (2022)

Depo-Provera® Treatment Does Not Abrogate Protection from Intravenous SIV Challenge in Female Macaques Immunized with an Attenuated AIDS Virus
por: Genescà, Meritxell, et al.
Publicado: (2010)

The seahorse (Hippocampus comes L.) extract ameliorates sperm qualities, testosterone level, and serum biochemistry in rats induced by depo medroxyprogesterone acetate
por: Mundijo, Trisnawati, et al.
Publicado: (2023)

Depo Medroxyprogesterone (DMPA) Promotes Papillomavirus Infections but Does Not Accelerate Disease Progression in the Anogenital Tract of a Mouse Model
por: Hu, Jiafen, et al.
Publicado: (2022)

Conjunctival Necrosis due to Subconjunctival Methylprednisolone (Depo-Medrol™) Acetate Injection
por: van Zyl, L. M., et al.
Publicado: (2010)

Levonorgestrel release rates measured through analysis of two-rod contraceptive explants
por: Fuchs, Rachael, et al.
Publicado: (2020)

Hypercalcemia after the Discontinuation of Medroxyprogesterone Acetate
por: Yuasa-Shibasaki, Erina, et al.
Publicado: (2017)

Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results
por: Okegbe, Tishina, et al.
Publicado: (2019)

Self-administered subcutaneous medroxyprogesterone acetate for improving contraceptive outcomes: a systematic review and meta-analysis
por: Nabhan, Ashraf, et al.
Publicado: (2021)

Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate
por: Curtis, Kathryn M., et al.
Publicado: (2021)

The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
por: Canney, P. A., et al.
Publicado: (1988)

Comparison of Two Different Injectable Contraceptive Methods: Depo-medroxy Progesterone Acetate (DMPA) and Cyclofem
por: Veisi, Firoozeh, et al.
Publicado: (2013)

A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection()()()
por: Cover, Jane, et al.
Publicado: (2017)

Trends in subcutaneous depot medroxyprogesterone acetate (DMPA-SC) use in Burkina Faso, the Democratic Republic of Congo and Uganda
por: Anglewicz, Philip, et al.
Publicado: (2019)

A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug–Drug Interactions With Antiretroviral and Antituberculosis Treatment
por: Francis, Jose, et al.
Publicado: (2021)

Inhibitory Effects of Medroxyprogesterone Acetate on Mouse Endometrial Carcinogenesis
por: Niwa, Kenji, et al.
Publicado: (1995)

Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study()()()
por: Cover, Jane, et al.
Publicado: (2017)

Characteristics associated with use of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Burkina Faso, Democratic Republic of Congo, and Uganda
por: Anglewicz, Philip, et al.
Publicado: (2021)

Patient’s experience and satisfaction with self-administered subcutaneous depot medroxyprogesterone acetate use during the first year of COVID-19()()
por: Smith, Tiffany Joyce, et al.
Publicado: (2023)

Implementation strategies to scale up self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception: a scoping review
por: Aderoba, Adeniyi Kolade, et al.
Publicado: (2023)

Health care provider and client experiences of counselling on depot medroxyprogesterone acetate subcutaneous (DMPA-SC) for self-injection in Malawi
por: Porter Erlank, Chelsey, et al.
Publicado: (2023)

ALICE proverà a fare un Big Ban in miniatura
por: Prestinenza, Luigi
Publicado: (2005)

Factors Affecting Continued Use of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC): A Secondary Analysis of a 1-Year Randomized Trial in Malawi
por: Burke, Holly M., et al.
Publicado: (2019)

Safety Evaluation of EXPAREL (DepoFoam Bupivacaine) Administered by Repeated Subcutaneous Injection in Rabbits and Dogs: Species Comparison
por: Richard, Brigitte M., et al.
Publicado: (2011)

Effect of medroxyprogesterone acetate on the response of the rat mammary gland to carcinogenesis.
por: Russo, I. H., et al.
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_6r3mu21jkuhn6ebij5q5b0h2gp